• Even though considered the second most common cause of ESRD, hypertensive nephrosclerosis has been histologically confirmed in very few cases • The causal relationship with hypertension is still a subject for debate
• The most characteristic microscopic lesion is hyalinosis of afferent arterioles • The vascular changes cause glomerular ischemia (retraction of the glomerular tuft with focal or global sclerosis), and in some areas, interstitial fibrosis and tubular atrophy
• In other cases the hyalinization of afferent arterioles initially causes glomerular hypertrophy and, in the long term glomerulosclerosis lesions that would favor the development of proteinuria and disease progression • These abnormalities are more frequent in black patients
• Hypertensive nephropathy is more frequent in African Americans • Pharmacologic treatment of mild-tomoderate hypertension in African Americans has little impact on the incidence of CKD, whereas it significantly reduces the progression in Caucasians Cumulative Incidence of the Composite Primary Outcome, According to Baseline Proteinuria Status. Among patients with baseline proteinuria, which was defined as a urinary protein-to-creatinine ratio (P:C) of more than 0.22, those who received intensive blood-pressure control had a significantly lower cumulative incidence of the composite primary outcome (a doubling of the serum creatinine level, end-stage renal disease, or death) than those who received standard bloodpressure control (hazard ratio in the intensive-control group, 0.73; 95% confidence interval [CI] , 0.58 to 0.93; P=0.01). However, the between-group difference was not significant among patients with a P:C of 0.22 or less (hazard ratio, 1.18; 95% CI, 0.93 to 1.50; P=0.16). The values at the bottom of the graph areON TARGET
• After a 3-week run-in period, 25 620 participants were randomly assigned to ramipril 10 mg a day, telmisartan 80 mg a day, or to a combination of both drugs • The primary renal outcome was a composite of dialysis, doubling of serum creatinine, and death
• The number of events for the composite primary outcome was similar for telmisartan and ramipril hazard ratio but was increased with combination therapy (HR 1·09, 1·01-1·18, p=0·037) • And authors concluded that even though combination therapy reduces proteinuria to a greater extent than monotherapy, it worsens major renal outcomes
